H-Leu-OH (Synonyms: Leu, NSC 46709, Pentanoic Acid) |
| Katalog-Nr.GA10282 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61-90-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway[1].
L-Leucine (10 mM) treatment impairs endocrine progenitor cell development[1].In E13.5 rat pancreatic explants, in absence of added L-Leucine, Ngn3 mRNA levels increased after 1 day of culture, peaked on day 3, and then decreased. When L-Leucine is added, a dramatic decrease is observed in Ngn3 mRNA levels. This decrease in Ngn3 mRNA levels was paralleled by a decrease in the number of Ngn3-expressing cells (4728±408 vs. 959±28; PNgn3, its target Insm1, and insulin[1]. Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. L-Leucine increases intracellular HIF-1α levels and activates the HIF-1α signaling pathway, and these two effects are mediated by the mTOR signaling pathway. This process results in Ngn3 repression and, consequently, decreases β-cell differentiation[1].
References:
[1]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *